Latest Breaking News On - Julip miller - Page 3 : comparemela.com

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 | The Kingston Whig Standard

Philadelphia, Pennsylvania and Oxford, United Kingdom (Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP),

Sao pauloUnited statesUnited kingdomDana lynchCintia piccinaJulip millerAdrian rawcliffeExchange commissionPostmedia network incDrug administrationGene strategy program management officeCompany sarcoma franchiseCorporate communicationsUniversity of sao pauloNewsfile corpCorporate affairs

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company s Sarcoma Franchise

Cintia Piccina returns as Chief Commercial Officer effective March 18, 2024 Philadelphia, Pennsylvania and Oxford, United Kingdom (Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced the reappointment of Cintia Piccina as Chief Commercial Officer effective March 18, 2024. Cintia served in this role from January 2022 to March 2023. Cintia will lead a rapidly expanding comme

United statesSao pauloCintia piccinaDana lynchJulip millerAdrian rawcliffeUnited newsfile corpCorporate communicationsGene strategy program management officeDrug administrationExchange commissionCorporate affairsUniversity of sao pauloChief commercial officerChief executive officerViral specifict cell

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJulip millerDana lynchCorporate affairsExchange commissionUnited newsfile corpCorporate communicationsPrivate securities litigation reform actAnnual reportQuarterly reportsCurrent reportsSenior director

Adaptimmune Announces U S FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Adaptimmune Announces U S FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDennis williamsDana lynchAdrian rawcliffeJulip millerCorporate affairsDrug administrationStage developmentExchange commissionUnited newsfile corpConnective tissue oncology societyCorporate communicationsBiologics license applicationPrescription drug user fee actChief executive officerLate stage development

Adaptimmune Announces U S FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Adaptimmune Therapeutics plc , a company redefining the treatment of solid tumor cancers with cell therapy, today announced that the U.S. Food and Drug Administration has accepted for priority review.

United statesDana lynchAdrian rawcliffeJulip millerDennis williamsDrug administrationStage developmentCorporate communicationsConnective tissue oncology societyExchange commissionUnited newsfile corpCorporate affairsBiologics license applicationPrescription drug user fee actChief executive officerLate stage development